Medexus Pharmaceuticals Inc (MDP.TO) has shown steady performance this week, reflecting positive market sentiment.
As of the latest trading session, Medexus Pharmaceuticals Inc has seen a modest increase in its stock price, closing at C$5.06, up 0.20% for the day and 2.05% over the week. The company continues to make strides in the healthcare sector, particularly with its focus on GRAFAPEX (treosulfan) for Injection.
Advertisement
Medexus Pharmaceuticals Inc
MDP.TO
MDP.TO
Medexus Pharmaceuticals Inc
WealthAwesomeAdvertisement
Market cap
$160.20M
52W high
$5.25
52W low
$2.47
1W change
+2.05%
Beta
1.84
Analyst Price Targets
Based on analyst covering MDP
Wall Street analysts forecast MDP stock price to rise 36.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.81
+36.7% Upside
Current Price
C$4.98
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDP's historical volatility
30-Day Vol
49.8%
Annualized
90-Day Vol
42.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$5.95
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$5.29 | C$4.45 – C$6.28 |
| 60 trading days | C$5.61 | C$4.40 – C$7.15 |
| 90 trading days | C$5.95 | C$4.42 – C$8.02 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Despite the absence of major new announcements this week, Medexus has maintained solid stock performance, buoyed by its recent fiscal results and product developments. Investors may want to keep an eye on upcoming earnings reports and product updates.
61.17% Year-to-Date Increase
Medexus Pharmaceuticals Inc has recorded a substantial 61.17% increase in its stock price year-to-date, showcasing strong investor interest and market confidence.
Bull case
The company recently reported strong fiscal results for 2026, highlighting the solid performance of its product offerings. This positive momentum could draw even more investor interest as the company's market cap grows.
Bear case
Medexus is currently operating at a loss, with a negative profit margin and return on equity. This situation may raise concerns for risk-averse investors about the company's long-term viability.
Price Action Overview
Advertisement
Medexus Pharmaceuticals Inc closed at C$5.06, reflecting a daily gain of 0.20% and a weekly increase of 2.05%. The stock's year-to-date performance has been impressive, with a total increase of 61.17%, indicating a strong recovery and investor confidence.
Recent Company Developments
While there were no significant announcements this week, Medexus has been in the news for its fiscal year 2026 results, which highlighted the strong performance of its GRAFAPEX product. Additionally, the company announced a license and supply agreement for UM171 cell therapy in Canada earlier this year, which could expand its product portfolio.
Technical Picture
Medexus is currently trading above its 50-day moving average of C$4.58, which is 10.4% higher than the current price, and significantly above its 200-day moving average of C$3.49, a 44.9% increase. The stock has traded within a 52-week range of C$2.47 to C$5.25, indicating it is currently near the upper end of this range. Additionally, the stock has a beta of 1.84, suggesting higher volatility compared to the broader market.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
